卡培他滨治疗胃癌疗效及安全性的系统评价  

Systematic Review on Therapeutic Effect and Safety Evaluation of Capecitabine in Patients with Gastric Carcinoma

作　　者：郭佳栋[1] 冯变玲[1] 张雪梅[1] 蔡佳慧[2] 赵妍[2] 王丽云[2] 

机构地区：[1]西安交通大学医学部药学院,西安710061 [2]西安交通大学医学部公共卫生学院,西安710061

出　　处：《药物流行病学杂志》2016年第2期69-73,共5页Chinese Journal of Pharmacoepidemiology

基　　金：国家社科基金资助项目(编号:13BGL132)

摘　　要：目的:系统评价胃癌患者使用卡培他滨的疗效和安全性。方法:检索国内外发表的关于卡培他滨治疗胃癌的中英文文献,对符合纳入标准的随机对照试验进行系统评价。结果:最终纳入8篇文献,合计427例患者。卡培他滨单药与替吉奥、多西他赛+顺铂比较疗效,差异无统计学意义(P>0.05)。卡培他滨单药发生口腔黏膜炎(26.7%)和手足综合症(49.8%)的频率较高;替吉奥给药方案与卡培他滨单药相比毒性小;多西他赛+顺铂给药更易发生恶心/呕吐(P<0.05);卡培他滨+奥沙利铂给药更易发生白细胞减少(P<0.05);FOLFOX4给药更易发生白细胞减少(P<0.05)和恶心/呕吐(P<0.05)。结论:常规剂量下替吉奥与卡培他滨单药相比毒性更小,卡培他滨发生口腔黏膜炎和手足综合征的频率较高。总体而言,卡培他滨单药给药安全性较好。Objective：Systematically review on therapeutic effect and chemotherapy safety of capeeitabine in the treatment of the gastric carcinoma patients. Methods： Chinese and foreign related literature about capecitabine in the treatment of the gastric carcinoma patients were retrieved, systematic review of randomized controlled trial which was included in the studies. Results： 8 literature and about 427 patients were chosen from all the papers. Into the study through the analysis, there was no significant difference between capecitabine, S-1, docetaxel and cisplatin about the treatment effect （P 〉 0.05 ）. Patients with eapecitabine single-agent, stomatitis （26.7%） and hand-foot syndrome （49.8 % ） occurred more often; results were better when S-1 dosage regimen compared with eapeeitabine single-agent, patients use capecitabine and cisplatin was more vulnerable to have nausea/vomiting （ P 〈 0.05 ） ; leukopenia occurred more often when patient have capeeitabine and oxaliplatin （ P 〈 0.05 ） , nausea/vomiting （ P 〈 0.05 ） and leukopenia （ P 〈 0.05 ） occurred more often when patient had FOLFOX4. Conclusion： Results were better when S-1 dosage regimen compared with capecitabine single agent. Stomatitis and hand-foot syndrome occurred more often when used eapeeitabine. In conclusion, the safety of the eapeeitabine was acceptable.

关 键 词：META分析 胃癌 卡培他滨 药品安全性 随机对照实验 

分 类 号：R979.1[医药卫生—药品]